These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Clinical Translation and First In-Human Use of [ Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832 [TBL] [Abstract][Full Text] [Related]
23. Comparison of Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020 [TBL] [Abstract][Full Text] [Related]
25. Examining Absorbed Doses of Indigenously Developed Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495 [No Abstract] [Full Text] [Related]
26. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions. Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion. Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254 [TBL] [Abstract][Full Text] [Related]
28. Head-to-Head Comparison of Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731 [No Abstract] [Full Text] [Related]
29. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602 [TBL] [Abstract][Full Text] [Related]
31. [ Peters SMB; Hofferber R; Privé BM; de Bakker M; Gotthardt M; Janssen M; de Lange F; Muselaers CHJ; Mehra N; Witjes JA; Costa PF; Nagarajah J; Konijnenberg MW; Jentzen W Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1101-1112. PubMed ID: 34623453 [TBL] [Abstract][Full Text] [Related]
32. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971 [TBL] [Abstract][Full Text] [Related]
33. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency. Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470 [TBL] [Abstract][Full Text] [Related]
34. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using Baum RP; Schuchardt C; Singh A; Chantadisai M; Robiller FC; Zhang J; Mueller D; Eismant A; Almaguel F; Zboralski D; Osterkamp F; Hoehne A; Reineke U; Smerling C; Kulkarni HR J Nucl Med; 2022 Mar; 63(3):415-423. PubMed ID: 34168013 [TBL] [Abstract][Full Text] [Related]